These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23688558)

  • 1. Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
    Kang S; Cooper G; Dunne SF; Luan CH; James Surmeier D; Silverman RB
    Bioorg Med Chem; 2013 Jul; 21(14):4365-73. PubMed ID: 23688558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
    Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
    Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Affinity of Isradipine for L-Type Ca
    Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
    J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
    Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
    Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cav1.4alpha1 subunits can form slowly inactivating dihydropyridine-sensitive L-type Ca2+ channels lacking Ca2+-dependent inactivation.
    Koschak A; Reimer D; Walter D; Hoda JC; Heinzle T; Grabner M; Striessnig J
    J Neurosci; 2003 Jul; 23(14):6041-9. PubMed ID: 12853422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
    Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
    Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease.
    Kang S; Cooper G; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
    J Med Chem; 2013 Jun; 56(11):4786-97. PubMed ID: 23651412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding mechanisms of 1,4-dihydropyridine derivatives to L-type calcium channel Cav1.2: a molecular modeling study.
    Xu L; Li D; Tao L; Yang Y; Li Y; Hou T
    Mol Biosyst; 2016 Feb; 12(2):379-90. PubMed ID: 26673131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 1,4-dihydropyridine derivatives with calcium channel blocking activity.
    Bladen C; Gündüz MG; Şimşek R; Şafak C; Zamponi GW
    Pflugers Arch; 2014 Jul; 466(7):1355-63. PubMed ID: 24149495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-/T-type calcium channel blockers.
    Teleb M; Rizk OH; Zhang FX; Fronczek FR; Zamponi GW; Fahmy H
    Bioorg Chem; 2019 Jul; 88():102915. PubMed ID: 31005784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
    Wang QM; Xu YY; Liu S; Ma ZG
    Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ca
    Toyoda F; Mesirca P; Dubel S; Ding WG; Striessnig J; Mangoni ME; Matsuura H
    Sci Rep; 2017 Aug; 7(1):7869. PubMed ID: 28801600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
    Ilijic E; Guzman JN; Surmeier DJ
    Neurobiol Dis; 2011 Aug; 43(2):364-71. PubMed ID: 21515375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-/T-type calcium channel blocking activities.
    Teleb M; Rizk OH; Zhang FX; Fronczek FR; Zamponi GW; Fahmy H
    Bioorg Chem; 2019 Mar; 83():354-366. PubMed ID: 30408648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive.
    Lin M; Aladejebi O; Hockerman GH
    Eur J Pharmacol; 2011 Nov; 670(1):105-13. PubMed ID: 21910984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain.
    Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H
    Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca
    Cooper G; Kang S; Perez-Rosello T; Guzman JN; Galtieri D; Xie Z; Kondapalli J; Mordell J; Silverman RB; Surmeier DJ
    ACS Chem Biol; 2020 Sep; 15(9):2539-2550. PubMed ID: 32881483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitory action of Biginelli-type dihydropyrimidines on depolarization-induced arterial smooth muscle contraction.
    Cernecka H; Veizerova L; Mensikova L; Svetlik J; Krenek P
    J Pharm Pharmacol; 2012 May; 64(5):735-41. PubMed ID: 22471370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focusing on C-4 position of Hantzsch 1,4-dihydropyridines: Molecular modifications, enantioseparation, and binding mechanism to L- and T-type calcium channels.
    Akman D; Denzinger K; Huang S; Lee JT; Nafie JW; Wolber G; Zamponi GW; Armstrong DW; Gündüz MG
    Eur J Med Chem; 2022 Dec; 244():114787. PubMed ID: 36209630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent.
    Huang H; Ng CY; Yu D; Zhai J; Lam Y; Soong TW
    Nat Commun; 2014 Jul; 5():4481. PubMed ID: 25057870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.